Skip to content

Clinical trials

Withdrawn Leukemia, Myeloid, Acute trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Status: Withdrawn Clear all

144 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20021
20043
20062
20073
20083
20091
20103
20113
20123
20133
20144
20155
20166
20179
20189
201910
202010
20213
202212
202314
202413
20255
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Withdrawn144

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center9
Masonic Cancer Center, University of Minnesota6
Fred Hutchinson Cancer Center4
Institute of Hematology & Blood Diseases Hospital, China4
Children's Oncology Group3
City of Hope Medical Center3
National Cancer Institute (NCI)3
Novartis Pharmaceuticals3
University of Florida3
University of Medicine and Dentistry of New Jersey3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute144
Myelodysplastic Syndromes42
Precursor Cell Lymphoblastic Leukemia-Lymphoma36
Leukemia26
Recurrence18
Leukemia, Lymphocytic, Chronic, B-Cell17
Burkitt Lymphoma16
Congenital Abnormalities16
Leukemia, Myelomonocytic, Chronic16
Lymphoma, Non-Hodgkin15

Trials

Showing 26 to 50 of 144. Each trial links to its page on Pharma Observatory.

44 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.